Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281081> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4379281081 endingPage "TPS8609" @default.
- W4379281081 startingPage "TPS8609" @default.
- W4379281081 abstract "TPS8609 Background: The PACIFIC trial (NCT02125461) established up to 12 months of consolidation therapy with durvalumab as standard of care (SoC) for patients with unresectable stage III non-small-cell lung cancer (NSCLC) and no disease progression after platinum-based cCRT. To improve outcomes further in this population, novel immunotherapy combinations that build on the backbone of PD-L1 inhibition with durvalumab are being explored. Domvanalimab (AB154) is a Fc-silent humanized IgG1 monoclonal antibody that blocks interaction of the T cell immunoreceptor with Ig and ITIM domains (TIGIT; upregulated by immune cells) with CD112 and CD155 (expressed by tumor and antigen-presenting cells), reducing inhibition of T cells and natural killer cells and, thereby, promoting antitumor activity. The combination of TIGIT inhibition with PD-(L)1 inhibition has shown encouraging activity in phase 1 and 2 trials in metastatic NSCLC, with enriched benefit observed among patients with PD-L1 positive tumors (Rodriguez-Abreu, et al. 2020; Niu, et al. 2020). In ARC-7 (NCT04262856), a randomized, phase 2 trial, the combination of domvanalimab and PD-1 inhibition was associated with improvement in progression-free survival (PFS) versus PD-1 inhibition alone (HR, 0.55; 95% CI, 0.31–1.0) in treatment-naïve patients with metastatic NSCLC and high PD-L1 expression (tumor proportion score ≥50%) (Johnson, et al. 2022). PACIFIC-8 (NCT05211895) is assessing the efficacy and safety of durvalumab combined with domvanalimab as consolidation therapy in patients with PD-L1 positive, unresectable stage III NSCLC and no disease progression after platinum-based cCRT. Methods: PACIFIC-8 is a phase 3, double-blind, placebo-controlled, randomized, global trial. Eligible patients (aged ≥18 years) must have PD-L1 positive, unresectable stage III NSCLC (tumor cell [TC] expression ≥1% by central lab; VENTANA SP263 IHC assay), WHO performance status 0/1, documented EGFR/ALK wild-type tumor status, and not have progressed following definitive, platinum-based cCRT (≥2 cycles). Approximately 860 patients will be randomized (1:1) to receive SoC durvalumab (1500 mg IV) combined with either domvanalimab (20 mg/kg IV) or placebo, every 4 weeks for up to 12 months. The primary endpoint is PFS (RECIST v1.1) by blinded independent central review (BICR) in patients with PD-L1 TC ≥50%. Secondary endpoints include PFS (RECIST v1.1; BICR) in patients with PD-L1 TC ≥1%, overall survival, objective response rate and duration of response (RECIST v1.1; BICR), safety/tolerability, and patient-reported outcomes. Trial enrollment is ongoing. Previously presented at the European Society for Medical Oncology (ESMO) Congress 2022, FPN (Final Publication Number): 971TiP, Mustafa Özgüroğlu et al. – Reused with permission. Clinical trial information: NCT05211895 ." @default.
- W4379281081 created "2023-06-05" @default.
- W4379281081 creator A5011519603 @default.
- W4379281081 creator A5023874099 @default.
- W4379281081 creator A5037237706 @default.
- W4379281081 creator A5044471960 @default.
- W4379281081 creator A5044613951 @default.
- W4379281081 creator A5064089801 @default.
- W4379281081 creator A5069589468 @default.
- W4379281081 creator A5073851139 @default.
- W4379281081 creator A5091892222 @default.
- W4379281081 date "2023-06-01" @default.
- W4379281081 modified "2023-10-16" @default.
- W4379281081 title "Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)." @default.
- W4379281081 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.tps8609" @default.
- W4379281081 hasPublicationYear "2023" @default.
- W4379281081 type Work @default.
- W4379281081 citedByCount "0" @default.
- W4379281081 crossrefType "journal-article" @default.
- W4379281081 hasAuthorship W4379281081A5011519603 @default.
- W4379281081 hasAuthorship W4379281081A5023874099 @default.
- W4379281081 hasAuthorship W4379281081A5037237706 @default.
- W4379281081 hasAuthorship W4379281081A5044471960 @default.
- W4379281081 hasAuthorship W4379281081A5044613951 @default.
- W4379281081 hasAuthorship W4379281081A5064089801 @default.
- W4379281081 hasAuthorship W4379281081A5069589468 @default.
- W4379281081 hasAuthorship W4379281081A5073851139 @default.
- W4379281081 hasAuthorship W4379281081A5091892222 @default.
- W4379281081 hasConcept C121608353 @default.
- W4379281081 hasConcept C126322002 @default.
- W4379281081 hasConcept C143998085 @default.
- W4379281081 hasConcept C2775949291 @default.
- W4379281081 hasConcept C2777701055 @default.
- W4379281081 hasConcept C2777742743 @default.
- W4379281081 hasConcept C2779118045 @default.
- W4379281081 hasConcept C2780057760 @default.
- W4379281081 hasConcept C2908647359 @default.
- W4379281081 hasConcept C71924100 @default.
- W4379281081 hasConcept C99454951 @default.
- W4379281081 hasConceptScore W4379281081C121608353 @default.
- W4379281081 hasConceptScore W4379281081C126322002 @default.
- W4379281081 hasConceptScore W4379281081C143998085 @default.
- W4379281081 hasConceptScore W4379281081C2775949291 @default.
- W4379281081 hasConceptScore W4379281081C2777701055 @default.
- W4379281081 hasConceptScore W4379281081C2777742743 @default.
- W4379281081 hasConceptScore W4379281081C2779118045 @default.
- W4379281081 hasConceptScore W4379281081C2780057760 @default.
- W4379281081 hasConceptScore W4379281081C2908647359 @default.
- W4379281081 hasConceptScore W4379281081C71924100 @default.
- W4379281081 hasConceptScore W4379281081C99454951 @default.
- W4379281081 hasIssue "16_suppl" @default.
- W4379281081 hasLocation W43792810811 @default.
- W4379281081 hasOpenAccess W4379281081 @default.
- W4379281081 hasPrimaryLocation W43792810811 @default.
- W4379281081 hasRelatedWork W2745896026 @default.
- W4379281081 hasRelatedWork W2802256694 @default.
- W4379281081 hasRelatedWork W2923986778 @default.
- W4379281081 hasRelatedWork W2969038597 @default.
- W4379281081 hasRelatedWork W2981562389 @default.
- W4379281081 hasRelatedWork W3019495616 @default.
- W4379281081 hasRelatedWork W3154458198 @default.
- W4379281081 hasRelatedWork W3169257134 @default.
- W4379281081 hasRelatedWork W4212773896 @default.
- W4379281081 hasRelatedWork W4280643539 @default.
- W4379281081 hasVolume "41" @default.
- W4379281081 isParatext "false" @default.
- W4379281081 isRetracted "false" @default.
- W4379281081 workType "article" @default.